Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.

Weisong LiKai ZhangWenjun WangYuanyuan LiuJianming HuangMeihong ZhengLing LiXinyu ZhangMinjuan XuGuofang ChenLiefeng WangShuyong Zhang

Published in: Journal of experimental & clinical cancer research : CR (2024)

These findings provide a preclinical framework supporting the potential of dual targeting HER2 and VEGFR as a promising therapeutic strategy to improve outcomes in patients with OC.

Keyphrases

vascular endothelial growth factor
cancer therapy
cell therapy
human health
stem cells
metabolic syndrome
risk assessment
skeletal muscle
weight loss
insulin resistance